

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A pharmaceutical composition comprising an adequate pharmaceutical carrier or diluent and a sufficient amount of an element selected from the group consisting of ~~the~~ a apolipoprotein L-1, a ~~pharmaceutical~~ pharmaceutically active fragment thereof, a polynucleotide encoding said polypeptide, a cell transformed by said polynucleotide ~~or~~ and an inhibitor directed against said apolipoprotein L-1.

2. **(Currently amended)** The pharmaceutical composition according to claim 1, wherein the apolipoprotein L-1 is ~~the~~ a human apolipoprotein L-1 corresponding to the sequence of SEQ. ID. NO: 1 or an homologue polypeptide.

3. **(Currently amended)** The pharmaceutical composition of claim 2, wherein the pharmaceutically active fragment of the human apolipoprotein L-1 is selected from the group consisting of ~~the~~ a sequence starting from the amino acid 1 up to the amino acid 342, ~~the~~ a sequence starting from the amino acid 343 to the amino acid 398, ~~the~~ a sequence starting from the amino acid 340 up to the amino acid 362 and ~~the~~ a sequence starting from the amino acid 356 up to the amino acid 398 of ~~the~~ a human polypeptide apolipoprotein sequence of SEQ. ID. NO: 1.

4. **(Currently amended)** The pharmaceutical composition according to claim 1, wherein the inhibitor directed against apolipoprotein L-1 is ~~the~~ a trypanosoma serum resistance associated polypeptide, SRA, or a pharmaceutical active fragment thereof or any molecule which mimic ~~the~~ an interaction between the polypeptide SRA and the apolipoprotein L-1.

5. **(Currently amended)** The pharmaceutical composition according to claim 4, wherein the pharmaceutical active fragment of the Trypanosoma polypeptide SRA is ~~the~~ a fragment of said polypeptide, which interacts specifically with apolipoprotein L-1.

6. **(Currently amended)** The pharmaceutical composition according to claim 4, wherein the molecule which mimic the interaction between the polypeptide SRA and the apolipoprotein L-1 is an antibody (or a hyper variable portion thereof), directed against apolipoprotein L-1, ~~preferably, an antibody (or a hyper variable portion thereof) directed against the terminal fragment of apolipoprotein L-1,~~ which interacts with the Trypanosoma polypeptide SRA.

Int. Appl. No. : PCT/BE2003/000131  
Int. Filing Date : August 4, 2003

7. (Currently amended) The pharmaceutical composition according to claim 1, wherein the inhibitor is an anti-idiotypic antibody or a hyper variable portion thereof directed against the an anti-apolipoprotein L-1 antibody (or a hyper variable portion thereof).

8. (Currently amended) ~~Use of the pharmaceutical composition according to any of the preceding claims 1 to 7, for the manufacture of a medicament for the~~ A method of treatment and/or the prevention of diseases induced in mammals (including the human) by Trypanosoma, especially African Trypanosoma comprising introducing the pharmaceutical composition of Claim 1 to said mammals.

9. (Currently amended) Use The method according to claim 8, wherein the Trypanosoma are selected from the group consisting of *Trypanosoma brucei brucei*, *Trypanosoma brucei rhodesiense* and *Trypanosoma gambiense*.

10. (Currently amended) Use The method according to claim 8 ~~or 9~~ wherein said disease is for the treatment of Nagana induced in bovidae by Trypanosoma brucei brucei.

11. (Currently amended) A diagnostic kit comprising an element selected from the group consisting of the an apolipoprotein L-1, a fragment thereof, a polynucleotide encoding said apolipoprotein L-1 ~~or and~~ an inhibitor directed against said apolipoprotein.

12. (Currently amended) The diagnostic kit of claim 11, wherein the apolipoprotein L-1 is ~~the a~~ a human apolipoprotein L-1 or an homologue polypeptide.

13. (Currently amended) The diagnostic kit according to claim 11 ~~or 12~~, wherein said inhibitor is ~~the a~~ a trypanosoma polypeptide SRA or a fragment thereof which interacts with said apolipoprotein L-1 or an antibody (or a hyper variable portion thereof) directed against said apolipoprotein L-1.

14. (Currently amended) A non-human genetically modified mammal which is expressing a polynucleotide encoding the an apolipoprotein L-1 (~~preferably the human polypeptide apolipoprotein L-I or an homologue of said polypeptide~~) or an active pharmaceutical fragment thereof and wherein the mammal is resistant or tolerant to diseases induced by Trypanosoma, ~~especially Trypanosoma brucei brucei (Nagana).~~

15. (Currently amended) The mammal according to claim 14 which is a genetically modified bovidae.

16. (Currently amended) The mammal according to claim 14 ~~or 15~~, wherein the pharmaceutical active fragment of apolipoprotein is ~~the~~ a sequence starting from the amino acid 1 up to the amino acid 342 of SEQ ID NO: 1.

17. (Currently amended) A solid support ~~such as a chromatographic column~~ comprising, bound to the a surface of said solid support, an inhibitor ~~(preferably an antibody, the SRA polypeptide or a fragment thereof)~~ directed against the an apolipoprotein L-1 ~~and used for the recovery of said apolipoprotein L-I from a mammal, preferably a human body sample.~~

18. (Currently amended) A method for the recovering of apolipoprotein L-1 polypeptide from a mammal, ~~preferably a human body sample (such as human serum)~~, said method comprising the steps of:

- putting into contact said a sample obtained from said mammal with the solid support of claim 17,
- binding the apolipoprotein L-1 to said inhibitor, and
- eluting the a contaminant of said sample, and
- eluting the apolipoprotein L-1 bound to the inhibitor from said solid support.

19. (New) The pharmaceutical composition according to claim 6, wherein the antibody or a hyper variable portion thereof directed against apolipoprotein L-1 is an antibody or a hyper variable portion thereof directed against a terminal fragment of apolipoprotein L-1.

20. (New) The method of Claim 8, wherein said mammal is human.

21. (New) The method of Claim 8, wherein said Trypanosoma is African Trypanosoma.

22. (New) The non-human genetically modified mammal of Claim 14, wherein said apolipoprotein L-1 is a human polypeptide apolipoprotein L-I or an homologue of said polypeptide.

23. (New) The non-human genetically modified mammal of Claim 14, wherein said Trypanosoma is *Trypanosoma brucei brucei* (Nagana).

24. (New) The solid support of Claim 17, wherein said solid support is a chromatographic column.

25. (New) The solid support of Claim 17, wherein said inhibitor is an antibody, the SRA polypeptide or a fragment thereof.

**Int. Appl. No. : PCT/BE2003/000131**

**Int. Filing Date : August 4, 2003**

26. (New) The solid support of Claim 17, wherein said inhibitor is adapted for the recovery of said apolipoprotein L-1.

27. (New) The solid support of Claim 26, wherein said recovery is from a human body sample.

28. (New) The method of Claim 18, wherein said sample is a human body sample.

29. (New) The method of Claim 28, wherein said human body sample is human serum.